Wedbush reaffirmed their neutral rating on shares of Cogent Biosciences (NASDAQ:COGT – Free Report) in a report issued on Friday morning, Benzinga reports. They currently have a $10.00 price target on the technology company’s stock. A number of other research analysts have also commented on the company. Leerink Partnrs reiterated an outperform rating on shares […]